Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov;292(1):209-224.
doi: 10.1111/imr.12812. Epub 2019 Oct 8.

Future prospects for CD8+ regulatory T cells in immune tolerance

Léa Flippe  1   2   3 , Séverine Bézie  1   2   3 , Ignacio Anegon  1   2   3 , Carole Guillonneau  1   2   3
Affiliations
Review

Future prospects for CD8+ regulatory T cells in immune tolerance

Léa Flippe et al. Immunol Rev. 2019 Nov.

Abstract

CD8+ Tregs have been long described and significant progresses have been made about their phenotype, their functional mechanisms, and their suppressive ability compared to conventional CD4+ Tregs. They are now at the dawn of their clinical use. In this review, we will summarize their phenotypic characteristics, their mechanisms of action, the similarities, differences and synergies between CD8+ and CD4+ Tregs, and we will discuss the biology, development and induction of CD8+ Tregs, their manufacturing for clinical use, considering open questions/uncertainties and future technically accessible improvements notably through genetic modifications.

Keywords: CD8+ Treg; therapy; tolerance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic depicting identified mechanisms of action and markers of rat, mouse and human CD8+CD45RClow/- Tregs. Breg, regulatory B cell; Co‐stim, costimulatory molecules; DC, dendritic cell; EC, endothelial cell; IDO, indoleamine 2,3‐dioxygenase; Kyn, kynurenin; Mreg, regulatory macrophages; pDC, plasmacytoid dendritic cell; Trp, tryptophan. Bended arrows indicate conversion or induction. Up and down arrows indicate increase and decrease, respectively
Figure 2
Figure 2
CD8+ Treg‐based therapy process. In vitro steps are indicated in pink background, optional steps in blank background and clinical steps in blue background. CNI, calcineurin inhibitor; KI, knock‐in; KO, knock‐out; MMF, mycophenolate mofetil; Prdn, prednisolone; TAC, tacrolimus; UCB, umbilical cord blood
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Möller G. Do suppressor T cells exist? Scand J Immunol. 1988;27(3):247‐250. - PubMed
    1. Bézie S, Anegon I, Guillonneau C. Advances on CD8+ Treg cells and their potential in transplantation. Transplantation. 2018;102(9):1467‐1478. - PubMed
    1. Bézie S, Meistermann D, Boucault L, et al. Ex vivo expanded human non‐cytotoxic CD8+CD45RClow/− Tregs efficiently delay skin graft rejection and GVHD in humanized mice. Front Immunol. 2017;8:2014. - PMC - PubMed
    1. Guillonneau C, Hill M, Hubert F‐X, et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN‐gamma, and indoleamine 2,3‐dioxygenase. J Clin Invest. 2007;117(4):1096‐1106. - PMC - PubMed
    1. Xystrakis E, Cavailles P, Dejean AS, et al. Functional and genetic analysis of two CD8 T cell subsets defined by the level of CD45RC expression in the rat. J Immunol. 2004;173(5):3140‐3147. - PubMed

Publication types

MeSH terms

Substances